Publications by authors named "Polianna Mara Rodrigues Souza"

Article Synopsis
  • Population aging presents significant challenges for cancer care, especially in low- and middle-income countries (LMIC), including the diverse Latin American region.
  • This review highlights recent progress in Mexico, Brazil, and Chile regarding educational, research, and clinical efforts in geriatric oncology.
  • The initiatives aim to reshape healthcare professionals' attitudes towards older adult care and enhance treatment approaches for elderly cancer patients.
View Article and Find Full Text PDF

Objectives: To evaluate the results of the comprehensive geriatric assessment (CGA) before allogeneic hematopoietic stem cell (HSCT) transplantation in patients aged 60 years and over.

Methods: We evaluated all consecutive patients undergoing CGA before HSCT between September 2011 and July 2018 in a private hospital in Brazil. We also evaluated the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-SCI) and the Disease Risk Index (DRI).

View Article and Find Full Text PDF

The Brazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: Elderly was elaborated by nutritionists, nutrologists and hematologists physicians from 15 Brazilians reference centers in hematopoietic stem cell transplantation, in order to emphasize the importancy of nutritional status and the body composition during the treatment, as well as the main characteristics related to patient's nutritional assessment. Establishing the consensus, we intended to improve and standardize the nutritional therapy during the hematopoietic stem cell transplantation. The Consensus was approved by the Brazilian Society of Bone Marrow Transplantation.

View Article and Find Full Text PDF

Hematopoietic stem cell transplantation (HSCT) is an important treatment option for children with severe and refractory sickle cell disease (SCD) with debilitating clinical complications. HSCT with cells from the bone marrow of a HLA-identical sibling used in SCD has a low mortality risk, high cure rate, and high event-free survival rate after a median follow-up of 5-6 years. However, matched donors are found in only about 20% of the patients.

View Article and Find Full Text PDF